Fauci: Rules Of Trials/Science Mustn't Slip In Outbreaks
This article was originally published in Scrip
In the midst of a crisis like the recent Ebola outbreak that swept through Guinea, Liberia and Sierra Leone, killing more than 11,300 people and sickening nearly 29,000, it's tempting to just throw everything the medical community has to offer at it in an attempt to save lives – something drug and vaccine makers and others conducting clinical trials often are under public pressure to do in desperate situations.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.